Mounjaro sales dip amid price war as semaglutide generics gain groundMounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...
10 Apr, 2026, 09.22 AM IST
Mounjaro maker signs $2.7 billion deal on AI drug researchThe new deal builds on existing collaborations between the two companies, which struck a software licensing agreement in 2023, according to...
30 Mar, 2026, 10.20 AM IST
Cipla to sell Lilly's weight-loss drug in IndiaEli Lilly and Cipla have joined forces. Cipla will now market Lilly's popular weight-loss drug in India. The medication will be sold under ...
24 Oct, 2025, 02.51 PM IST
Popular US-based weight loss drug maker Eli Lilly plans to launch medicine in India next yearEli Lilly will launch Mounjaro in India in 2025. The drug treats type 2 diabetes and obesity. Lilly received marketing authorization in Jul...
21 Mar, 2025, 07.53 AM IST
Eli Lilly lays off 120 employees in India after Cipla saleThe sales team was informed of the decision at a virtual town hall organised last week in conjunction with the media announcement of the de...
11 Oct, 2021, 06.20 AM IST
BDR Pharma inks licensing pact with Eli Lilly for COVID-19 treatment drugBaricitinib has received restricted emergency use approval, for use in combination with Remdesivir, for treatment of suspected or laborator...
19 May, 2021, 02.20 PM IST
Eli Lilly inks pacts for COVID-19 drug Baricitinib with Torrent Pharma, Dr Reddy's, MSN LabsThe company has issued additional royalty-free, non-exclusive voluntary licences to Dr Reddy's, MSN Laboratories and Torrent Pharmaceutical...
13 May, 2021, 09.20 PM IST
MSN Labs ties up with Eli Lilly for baricitinib in IndiaAs part of the COVID treatment range, MSN has already launched Favilow (Favipiravir) in the strengths of 200mg, 400mg and 800mg and Oselow ...
13 May, 2021, 02.27 PM IST
Dr Reddy's inks licensing pact with Eli Lilly for COVID-19 treatment drugThe Hyderabad-based firm said it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company fo...
11 May, 2021, 11.31 PM IST
Lupin partners Eli Lilly to market diabetes drug 'Eglucent'According to the agreement, Lupin will market and sell Eglucent through its own specialty field force while Lilly will be responsible for m...
01 Dec, 2016, 12.57 PM IST
- Eli Lilly's to bet on original drugs to triple sales in India over next 5 years
Unlike other foreign drugmakers, it plans to stay away from acquisition of local firms or branded generics to boost its market share.
15 Sep, 2011, 04.14 AM IST
- HCL Tech in pact with Eli Lilly for developing technologies
HCL and Eli Lilly entered into a partnership for developing technologies & improving operational efficiencies to enhance latter's global co...
14 Jul, 2011, 11.41 AM IST
- Jubilant extends collaboration with Eli Lilly
Pharma company Jubilant Organosys has extended its four-year-old drug research collaboration with Eli Lilly for another five years.
02 Dec, 2009, 12.35 AM IST
- Sharekhan recommends ‘buy’ on Cadila Healthcare
Sharekhan has recommended ‘buy’ on Cadila Healthcare with a target price of Rs.372. At the current market price of Rs272, the stock is avai...
01 Apr, 2009, 01.45 PM IST
- Zydus eyes $ 300 million revenue generation with Eli Lilly
Zydus Cadila eyes large chunk of revenue generation from its new drug discovery pact with global drug giant Eli Lilly.
30 Mar, 2009, 02.37 PM IST
- Suven Life Sciences, US co enter deal on pre-clinical research
Suven Life Sciences has entered into an agreement with Eli Lilly to collaborate on the pre-clinical research of molecules in the therapeuti...
12 Mar, 2008, 04.22 PM IST
- Suven ties up with US-based pharma co
Suven Life Sciences Ltd has signed an agreement with US-based pharmaceutical firm Eli Lilly and Company to carryout pre-clinical research f...
29 Aug, 2006, 03.00 PM IST